half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-29. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two types of dried lotus seeds can be found commercially; brown peel and white. The former is harvested when the seed head of the lotus is ripe or nearly ripe and the latter is harvested when the seed head is still fully green but with almost fully developed seeds. White lotus seeds are de-shelled and de-membraned. At harvest, the bitter-tasting germ of most seeds is removed using a hollow needle. Brown peel lotus seeds are brown because the ripened seed has adhered to its membrane. The germ of these hard seeds is removed by cracking the seeds in half. Dried lotus seeds past their prime oxidize to a yellow brown color. However, some sellers of dried lotus seeds bleach their products with hydrogen peroxide, sodium hydroxide, or other chemicals.
== Structure == The thymus is an organ that sits behind the sternum in the upper front part of the chest, stretching upwards towards the neck. In children, the thymus is pinkish-gray, soft, and lobulated on its surfaces. At birth, it is about 4–6 cm long, 2.5–5 cm wide, and about 1 cm thick. It increases in size until puberty, where it may have a size of about 40–50 g, following which it decreases in size in a process known as involution. The thymus is located in the anterior mediastinum. It is made up of two lobes that meet in the upper midline, and stretch from below the thyroid in the neck to as low as the cartilage of the fourth rib. A capsule covers the lobes. The thymus lies behind the sternum, rests on the pericardium, and is separated from the aortic arch and great vessels by a layer of fascia. The left brachiocephalic vein may even be embedded within the thymus. In the neck, it lies on the front and sides of the trachea, behind the sternohyoid and sternothyroid muscles.
Laboratory mice Dogs Big cats Horses Cattle Chickens Bananaquit Gyrfalcon Kermode bears Rock pocket mice Domestic rabbits Antarctic fur seals Mammoth A study on unrelated British and Irish individuals demonstrated that over 80% of people with red hair and/or fair skin that tan poorly have a dysfunctional variant of the MC1R gene. This is compared to less than 20% in people with brown or black hair, and less than 4% in people showing a good tanning response. Asp294His (rs1805009) is a single nucleotide polymorphism (SNP) in the MC1R gene and it is associated with red hair and light skin type. Other SNPs in the gene, Arg151Cys and Arg160Trp, are also associated with red hair. The Out-of-Africa model proposes that modern humans originated in Africa and migrated north to populate Europe and Asia. These migrants most likely had a functional MC1R variant and, accordingly, dark hair and skin as displayed by indigenous Africans today. As humans migrated north, the absence of high levels of solar radiation in northern Europe and Asia relaxed the selective pressure on active MC1R, allowing the gene to mutate into dysfunctional variants without reproductive penalty, then propagate by genetic drift. Studies show the MC1R Arg163Gln allele has a high frequency in East Asia and may be part of the evolution of light skin in East Asian populations. No evidence is known for positive selection of MC1R alleles in Europe and there is no evidence of an association between the emergence of dysfunctional variants of MC1R and the evolution of light skin in European populations.
Sources: en.wikipedia.org
Function-Spacer-Lipid (FSL) Kode constructs (Kode Technology) are amphiphatic, water dispersible biosurface engineering constructs that can be used to engineer the surface of cells, viruses and organisms, or to modify solutions and non-biological surfaces with bioactives. FSL Kode constructs spontaneously and stably incorporate into cell membranes. FSL Kode constructs with all these aforementioned features are also known as Kode Constructs. The process of modifying surfaces with FSL Kode constructs is known as "koding" and the resultant "koded" cells, viruses and liposomes are respectively known as kodecytes, and kodevirions.
== Use and effects == A phase 1 dose-ranging clinical trial found that zalsupindole is non-hallucinogenic in humans across a dose range of 2 to 360 mg orally. Nonetheless, it produced changes in brain function as measured by quantitative electroencephalography (qEEG).
=== Injury resistance === HGH may build up connective tissue within muscles, at least in the short term. If these effects are real they "may promote resistance to injury or faster repair [but] would make the muscle no more capable of force generation". With the release of the Mitchell Report on December 13, 2007, 86 players were revealed to have used performance-enhancing drugs while playing in the Major Leagues. The report stated: "Players who use Human Growth Hormone apparently believe that it assists their ability to recover from injuries and fatigue".
Sources: en.wikipedia.org
Professor Mary Tara Marshall, Director, Dementia Services Development Centre at the University of Stirling. Lately Director, Age Concern Scotland. For services to Elderly People. Arthur Gordon Mason, Research Manager, Digi-Media Vision Ltd. For services to the Broadcasting Industry. Duncan Stuart Matthews, Head of Innovation and Growth Unit, National Westminster Bank plc. For services to Banking and to Industry. Kenneth McAlpine, . For services to the English Vineyard Association and to English Wine. James McIntosh McCabe, . For political service. Andrew Duncan McCracken, lately Principal Officer, Howdenhall/St. Katharine's Centre, Edinburgh. For services to Child Care. David Alexander McCubbin. For services to people with learning disabilities. Professor Damien Gerard McDonnell, Senior Principal Scientific Officer, the Defence Evaluation and Research Agency, Ministry of Defence. James Dobbie McFarlane, lately Major Projects Director, Engineering Division, Nuclear Electric plc. For services to the Nuclear Electric Industry. William McGinnis, . For services to the Sheet Metal Industry and to Industry. Roger McGough, Poet. For services to Poetry. Helen Frances McGrath, President, National Union of Knitwear, Footwear and Apparel Trades. For services to Industrial Relations. Stuart McKenzie. For services to the Sea Cadet Corps, Southern Area. Donald McNeill, lately Chief Executive, South Ayrshire Hospitals NHS Trust. For services to Health Care. Professor David Alan Redpath Michie, Artist. For services to Art Jean Monro. For services to Interior Design.
== Education == Foyer attended Portsmouth Polytechnic (now the University of Portsmouth) from 1971–74, achieving a BSc with Class II, Division I Honours in Biology (CNAA). From 1974–77 she attended the Department of Biochemistry, King's College London, where she completed her PhD. During this time Foyer also attended a course on immunology at Chelsea College, London. In 1998 Foyer was elected a Fellow of the Institute of Biology.
In 1922, after wartime experience had shown that the maintenance of 130 separate single-battalion infantry regiments was unwieldy, a number of large (four to five battalion) regiments were created, and numerous cavalry regiments amalgamated. The List of regiments of the Indian Army (1922) shows the reduced number of larger regiments. Until 1932 most Indian Army officers, both British and Indian, were trained at the Royal Military College, Sandhurst, after that date the Indian officers increasingly received their training at the Indian Military Academy in Dehradun which was established that year.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.